An update on new and emerging therapies for relapsing-remitting multiple sclerosis

American Journal of Managed Care

Volumn 19, Issue 17 SUPPL., 2013, Pages

  Weinstock Guttman, Bianca ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b JACOBS NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; NATALIZUMAB; OCRELIZUMAB; RITUXIMAB; TERIFLUNOMIDE; CROTONIC ACID DERIVATIVE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PROPANEDIOL DERIVATIVE; SPHINGOSINE; TOLUIDINE DERIVATIVE;

ARTICLE; DISEASE ACTIVITY; DISEASE CONTROL; DRUG APPROVAL; DRUG EFFICACY; HUMAN; MEDICATION COMPLIANCE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ANALOGS AND DERIVATIVES; FEMALE; FORECASTING; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ORAL DRUG ADMINISTRATION; PATIENT SAFETY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE III AS TOPIC; CROTONATES; DRUG APPROVAL; FEMALE; FORECASTING; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT SAFETY; PROGNOSIS; PROPYLENE GLYCOLS; SEVERITY OF ILLNESS INDEX; SPHINGOSINE; TOLUIDINES; TREATMENT OUTCOME;

EID: 84903217919     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (123)

1. Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med. 2011;78(2):161-175.
2. Calabresi PA. Diagnosis and management of multiple sclerosis. Am Fam Physician. 2004;70(10):1935-1944. (Pubitemid 39532194)
3. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008;7(12):1139-1151.
4. Berger JR. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies. Am J Manag Care. 2011;17(suppl 5, Improving):S146-S153.
5. Kita M. FDA-approved preventative therapies for MS: first-line agents. Neurol Clin. 2011;29(2):401-409.
6. Aubagio (teriflunomide) [prescribing information]. Cambridge, MA: Genzyme Corporation; September 2012.
7. Tecfidera (dimethyl fumarate) [prescribing information]. Cambridge, MA: Biogen Idec Inc; March 2013.
8. Novantrone (mitoxantrone) [prescribing information]. Rockland, MA: EMD Serono, Inc; 2007.
9. Miller RM, Happe LE, Meyer KL, Spear RJ. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians. J Manag Care Pharm. 2012;18(1):54-62.
10. Sperandeo K, Nogrady L, Moreo K, Prostko CR. Managed approaches to multiple sclerosis in special populations. J Manag Care Pharm. 2011;17(9, suppl C):S1-S19.
11. Hartung HP, Montalban X, Sorensen PS, Vermersch P, Olsson T. Principles of a new treatment algorithm in multiple sclerosis. Expert Rev Neurother. 2011;11(3):351-362.
12. Bruce JM, Lynch SG. Multiple sclerosis: MS treatment adherence - how to keep patients on medication? Nat Rev Neurol. 2011;7(8):421-422.
13. Wong J, Gomes T, Mamdani M, Manno M, O'Connor PW. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low. Can J Neurol Sci. 2011;38(3):429-433.
14. Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010;4:1-9.
15. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2011;18(1):69-77.
16. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256(4):568-576.
17. Krieger S. Multiple sclerosis therapeutic pipeline: opportunities and challenges. Mt Sinai J Med. 2011;78(2):192-206.
18. Fontoura P, Garren H. Multiple sclerosis therapies: molecular mechanisms and future. Results Probl Cell Differ. 2010;51:259-285.
19. Girouard N, Soucy N. Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents. Patient Prefer Adherence. 2011;5:101-108.
20. Gold R. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs. 2011;25(1):37-52.
21. Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol. 2011;10(11):1026-1034.
22. Minagar A, Alexander JS, Sahraian MA, Zivadinov R. Alemtuzumab and multiple sclerosis: therapeutic application. Expert Opin Biol Ther. 2010;10(3):421-429.
23. Rivera VM, Jeffery DR, Weinstock-Guttman B, Bock D, Dangond F. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. BMC Neurol. 2013;13(1):80.
24. Gold R, Wolinsky JS, Amato MP, Comi G. Evolving expectations around early management of multiple sclerosis. Ther Adv Neurol Disord. 2010;3(6):351-367.
25. Hawker K. Progressive multiple sclerosis: characteristics and management. Neurol Clin. 2011;29(2):423-434.
26. Hurwitz BJ. The diagnosis of multiple sclerosis and the clinical subtypes. Ann Indian Acad Neurol. 2009;12(4):226-230.
27. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005;4(5):281-288. (Pubitemid 40545039)
28. Limmroth V, Putzki N, Kachuck NJ. The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? a comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Ther Adv Neurol Disord. 2011;4(5):281-296.
29. Jacobs LD, Cookfair DL, Rudick RA, et al; the Multiple Sclerosis Collaborative Research Group Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39(3):285-294. (Pubitemid 26100751)
30. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis Study Group). Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-1504.
31. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655-661.
32. Paty DW, Li DK; UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):662-667. (Pubitemid 23121952)
33. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242-1249. (Pubitemid 44563835)
34. Jacobs LD, Beck RW, Simon JH, et al CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343(13):898-904.
35. Johnson KP, Brooks BR, Cohen JA, et al; The Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebocontrolled trial. Neurology. 1995;45(7):1268-1276.
36. Comi G, Filippi M, Wolinsky JS; European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001;49(3):290-297. (Pubitemid 32202781)
37. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9700):1503-1511.
38. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
39. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007;68(17):1390-1401. (Pubitemid 46659091)
40. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-923.
41. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124-1140. (Pubitemid 44394919)
42. Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand. 2006;113(5):283-287.
43. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology. 2002;59(10):1496-1506. (Pubitemid 35387053)
44. Smith B, Carson S, Fu R, et al. Drug class review: diseasemodifying drugs for multiple sclerosis: final update 1 report. http://www.ncbi.nlm.nih.gov/ books/NBK50570/. Portland, OR: Oregon Health & Science University; 2010.
45. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359(9316):1453-1460. (Pubitemid 34457761)
46. Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs. 2010;70(12):1545-1577.
47. Lalive PH, Neuhaus O, Benkhoucha M, et al. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs. 2011;25(5):401-414.
48. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009;72(23):1976-1983.
49. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903-914.
50. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10):889-897.
51. Ghezzi A, Grimaldi LM, Marrosu MG, et al. Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group - Italian Neurological Society. Neurol Sci. 2011;32(2):351-358.
52. Farrell RA, Giovannoni G. Current and future role of interferon beta in the therapy of multiple sclerosis. J Interferon Cytokine Res. 2010;30(10):715-726.
53. Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007;62(4):335-346. (Pubitemid 350105948)
54. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880.
55. Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18(2):143-152.
56. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
57. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
58. Warnke C, Stuve O, Hartung HP, Fogdell-Hahn A, Kieseier BC. Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2011;7:519-527.
59. Gilenya (fingolimod) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.
60. Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand. 2011;124(2):75-84.
61. Palmer AM. Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis. Curr Opin Investig Drugs. 2010;11(11):1313-1323.
62. Claussen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin Immunol. 2012;142(1):49-56.
63. O'Connor P, Wolinksy JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-1303.
64. Freedman MS, Wolinsky JS, Wamil B, et al. Oral teriflunomide plus glatiramer acetate in relapsing multiple sclerosis. Int J MS Care. 2011;13:9. Abstract P17.
65. Freedman MS, Wolinsky JS, Wamil B, et al. Teriflunomide added to interferon-beta in relapsing multiple sclerosis: a randomized phase II trial. Neurology. 2012;78(23):1877-1885.
66. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098- 1107.
67. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087-1097.
68. Kappos L, Gold R, Arnold D, et al. BG-12 effects on patientreported outcomes in relapsing-remitting multiple sclerosis: results from the DEFINE study. Presented at: the 5th Triennial Joint Meeting of the European and Americas Committees for Treatment and Research in Multiple Sclerosis; October 19-22, 2011; Amsterdam, Netherlands. Abstract P1071.
69. Agarwal S, Kappos L, Gold R, et al. Effects of BG-12 on quality of life in patients with relapsing-remitting multiple sclerosis: findings from the DEFINE study. Neurology. 2012;78. Abstract P07.102.
70. Giovannoni G, Gold R, Kappos L, et al. BG-12 increases the proportion of patients free of clinical and radiologic disease activity in relapsing-remitting multiple sclerosis: findings from the DEFINE study. Neurology. 2012;78. Abstract PD5.005.
71. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing- remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819- 1828.
72. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829-1839.
73. Giovannoni G, Gold R, Selmaj K, et al. A randomized, doubleblind, placebo-controlled study to evaluate the safety and efficacy of daclizumab HYP monotherapy in relapsingremitting multiple sclerosis: primary results of the SELECT trial. Presented at: the 5th Triennial Joint Meeting of the European and Americas Committees for Treatment and Research in Multiple Sclerosis; October 19-22, 2011; Amsterdam, Netherlands. Abstract 149.
74. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-688. (Pubitemid 351240747)
75. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsingremitting multiple sclerosis: a phase 2, randomised, placebocontrolled, multicentre trial. Lancet. 2011;378(9805):1779-1787.
76. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366(11):1000-1009.
77. O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66(6):894-900. (Pubitemid 43739766)
78. Confavreux C, Li DK, Freedman MS, et al. Long-term followup of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler. 2012;18(9):1278-1289.
79. O'Connor PW, Wolinsky JS, Miller A, et al. Teriflunomide in multiple sclerosis with relapses: outcomes by prior therapy in TEMSO. Int J MS Care. 2011;13:7. Abstract P14.
80. Wolinsky JS, Narayana PA, Nelson F, et al. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler. 2013;19(10):1310-1319.
81. Vermersch P, Czlonkowska A, Grimaldi LM, et al. A multicenter, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Int J MS Care. 2012;(suppl):9-10.
82. Linker RA, Lee DH, Stangel M, Gold R. Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies. Expert Rev Neurother. 2008;8(11):1683-1690.
83. Rostami Yazdi M, Mrowietz U. Fumaric acid esters. Clin Dermatol. 2008;26(5):522-526.
84. Moharregh-Khiabani D, Linker RA, Gold R, Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol. 2009;7(1):60-64.
85. Papadopoulou A, D'Souza M, Kappos L, Yaldizli O. Dimethyl fumarate for multiple sclerosis. Expert Opin Investig Drugs. 2010;19(12):1603-1612.
86. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372(9648):1463-1472.
87. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med. 2013;368(17):1657-1658.
88. Sweetser MT, Dawson KT, Bozic C. Manufacturer's response to case reports of PML. N Engl J Med. 2013;368(17):1659-1661.
89. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med. 2013;368(17):1658-1659.
90. Fox EJ. Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother. 2010;10(12):1789-1797.
91. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-1801.
92. Wray S. Alemtuzumab reduces risk of sustained accumulation of disability and relapse rate at years 1 and 2 in CAMMS223. Int J MS Care. 2011;13:31. Abstract S44.
93. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: posthoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011;10(4):338-348.
94. Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain. 2010;133(pt 8):2232-2247.
95. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012;78(14):1069-1078.
96. Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(3):298-304.
97. Selmaj K; on behalf of the CAMMS223 Study Group. Leukocyte dynamics following alemtuzumab treatment of relapsing-remitting multiple sclerosis: long-term follow-up of CAMMS223 patients. Presented at: the 5th Triennial Joint Meeting of the European and Americas Committees for Treatment and Research in Multiple Sclerosis; October 19-22, 2011; Amsterdam, Netherlands. Abstract P437.
98. Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis-a focus on alemtuzumab. Clin Immunol. 2012;142(1):25-30.
99. Havrdova E, Arnold D, Cohen J, et al. Infections in phase 3 study: comparison of alemtuzumab and Rebif® efficacy in multiple sclerosis I (CARE-MS I). Neurology. 2012;78. Abstract S41.007.
100. Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77(6):573-579.
101. Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009;119(7):2052-2061.
102. Selmaj K, Arnold D, Brinar V, et al. Incidence of autoimmunity in a phase 3 trial: comparison of alemtuzumab and Rebif® in multiple sclerosis I (CARE-MS I). Neurology. 2012;78. Abstract S41.006.
103. Kim SE. Daclizumab treatment for multiple sclerosis. Pharmacotherapy. 2009;29(2):227-235.
104. Martin R. Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis. Neurodegener Dis. 2008;5(1): 23-26. (Pubitemid 350261812)
105. Schippling DS, Martin R. Spotlight on anti-CD25: daclizumab in MS. Int MS J. 2008;15(3):94-98.
106. Stüve O, Greenberg BM. Anticipated benefits and surprising effects of daclizumab in multiple sclerosis. Lancet Neurol. 2010;9(4):337-338.
107. Ali EN, Healy BC, Stazzone LA, et al. Daclizumab in treatment of multiple sclerosis patients. Mult Scler. 2009;15(2):272- 274.
108. Schluns KS. Window of opportunity for daclizumab. Nat Med. 2011;17(5):545-547.
109. Martin R. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin Immunol. 2012;142(1):9-14.
110. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A. 2004;101(23):8705-8708. (Pubitemid 38745835)
111. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol. 2004;56(6):864-867. (Pubitemid 39578450)
112. Rose JW, Burns JB, Bjorklund J, et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology. 2007;69(8):785-789. (Pubitemid 47300936)
113. Rojas MA, Carlson NG, Miller TL, Rose JW. Long-term daclizumab therapy in relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord. 2009;2(5):291-297.
114. Multiple Sclerosis Trust. Daclizumab: information, education, research, and support. www.mstrust.org.uk/research/drugsindevelopment/daclizumab.jsp.
115. Gensicke H, Leppert D, Yaldizli Ö, et al. Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. CNS Drugs. 2012;26(1):11-37.
116. Giacomini PS, Bar-Or A. Laquinimod in multiple sclerosis. Clin Immunol. 2012;142(1):38-43.
117. Brück W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci. 2011;306(1-2):173-179.
118. Fernández O. Oral laquinimod treatment in multiple sclerosis. Neurologia. 2011;26(2):111-117.
119. Thöne J, Gold R. Laquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosis. Expert Opin Drug Metab Toxicol. 2011;7(3):365-370.
120. Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology. 2005;64(6):987-991. (Pubitemid 40388448)
121. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;371(9630):2085-2092. (Pubitemid 351842581)
122. Comi G, Abramsky O, Arbizu T, et al. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Mult Scler. 2010;16(11):1360-1366.
123. Karmon Y, Mehta BK, Weinstock-Gutman B. Other therapeutics in the pipeline and future directions. In: Rudick RA, Bermel RA, eds. Addressing Unmet Medical Needs in Relapsing-Remitting Multiple Sclerosis. London, UK: Future Medicine Ltd;2011:58-74.